Xenetic Biosciences Share Holder Equity 2013-2024 | XBIO

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Xenetic Biosciences share holder equity from 2013 to 2024. Share holder equity can be defined as the sum of preferred and common equity items

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Xenetic Biosciences share holder equity from 2013 to 2024. Share holder equity can be defined as the sum of preferred and common equity items

Related Stocks
Company Name	Market Cap
Zoetis (ZTS)	$88.7B
Takeda Pharmaceutical (TAK)	$47.3B
Merck (MKGAF)	$23.7B
Astellas Pharma (ALPMY)	$21.5B
Summit Therapeutics (SMMT)	$19B
Sandoz Group AG (SDZNY)	$17.5B
United Therapeutics (UTHR)	$15.4B
Shionogi (SGIOY)	$13.3B
Neurocrine Biosciences (NBIX)	$12.4B
Catalent (CTLT)	$11B
Orion OYJ (ORINY)	$7.4B
Revolution Medicines (RVMD)	$7.3B
Jazz Pharmaceuticals (JAZZ)	$6.9B
Ionis Pharmaceuticals (IONS)	$6.1B
Hikma Pharmaceuticals Plc (HKMPF)	$5.7B
Madrigal Pharmaceuticals (MDGL)	$5.1B
Crinetics Pharmaceuticals (CRNX)	$4.2B
Corcept Therapeutics (CORT)	$4.1B
Dyne Therapeutics (DYN)	$3.5B
AMNEAL PHARMACEUTICALS, INC (AMRX)	$2.7B
PTC Therapeutics (PTCT)	$2.7B
Arrowhead Pharmaceuticals (ARWR)	$2.5B
Catalyst Pharmaceuticals (CPRX)	$2.4B
Soleno Therapeutics (SLNO)	$2.1B
Recursion Pharmaceuticals (RXRX)	$1.9B
Centessa Pharmaceuticals (CNTA)	$1.8B
Xencor (XNCR)	$1.6B
BioCryst Pharmaceuticals (BCRX)	$1.6B
Harrow (HROW)	$1.5B
Cassava Sciences (SAVA)	$1.5B